Benefit/Risk Profile of Single-Inhaler Triple Therapy in COPD

Jean Bourbeau,1 Mona Bafadhel,2 Neil C Barnes,3,4 Chris Compton,3 Valentina Di Boscio,3 David A Lipson,5,6 Paul W Jones,3,7 Neil Martin,3,8 Gudrun Weiss,3 David MG Halpin9 1Respiratory Epidemiology and Clinical Research Unit, Department of Medicine, McGill University and Research Institute of the Mc...

Full description

Bibliographic Details
Main Authors:	Bourbeau J, Bafadhel M, Barnes NC, Compton C, Di Boscio V, Lipson DA, Jones PW, Martin N, Weiss G, Halpin DMG
Format:	Article
Language:	English
Published:	Dove Medical Press 2021-03-01
Series:	International Journal of COPD
Subjects:	all-cause mortality exacerbations hospitalizations ics laba lama
Online Access:	https://www.dovepress.com/benefitrisk-profile-of-single-inhaler-triple-therapy-in-copd-peer-reviewed-article-COPD

Similar Items

Indacaterol/glycopyrronium in symptomatic patients with COPD (GOLD B and GOLD D) versus salmeterol/fluticasone: ILLUMINATE/LANTERN pooled analysis
by: Vogelmeier C, et al.
Published: (2016-12-01)

Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial
by: Nicola C. Day, et al.
Published: (2020-06-01)

LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis
by: Rodrigo GJ, et al.
Published: (2017-03-01)

A Framework For Step Down Or Therapeutic Re-Organization For Withdrawal Of Inhaled Corticosteroids In Selected Patients With COPD: A Proposal For COPD Management
by: Micheletto C, et al.
Published: (2019-09-01)

Severe exacerbation and pneumonia in COPD patients treated with fixed combinations of inhaled corticosteroid and long-acting beta2 agonist
by: Yang HH, et al.
Published: (2017-08-01)

Effect of Recent Exacerbation History on the Efficacy of Once-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease in the FULFIL Trial
by: Panettieri Jr RA, et al.
Published: (2022-09-01)

Roflumilast: the fourth Mousquetaire in COPD pharmacological treatment
by: Bruno Balbi
Published: (2015-08-01)

Open and Closed Triple Inhaler Therapy in Patients with Uncontrolled Asthma
by: Serafeim-Chrysovalantis Kotoulas, et al.
Published: (2023-07-01)

A Delphi Consensus Document on the Use of Single-Inhaler Fixed-Dose Triple Therapies in COPD Patients
by: López-Campos JL, et al.
Published: (2020-07-01)

The Impact of Fixed Triple Therapy with Beclometasone/Formoterol/Glycopyrronium on Health Status and Adherence in Chronic Obstructive Pulmonary Disease (COPD) in an Italian Context of Real Life: The TRITRIAL Study Protocol
by: Richeldi L, et al.
Published: (2021-01-01)

Evaluation of Medication Adherence and Rescue Medication Use in Non-Exacerbating Patients with COPD Receiving Umeclidinium/Vilanterol or Budesonide/Formoterol as Initial Maintenance Therapy
by: Moretz C, et al.
Published: (2020-09-01)

Factors influencing pharmacological treatment in COPD: a comparison of 2005 and 2014
by: Josefin Sundh, et al.
Published: (2017-01-01)

Efficacy And Safety Of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (GFF MDI) Formulated Using Co-Suspension Delivery Technology In Chinese Patients With COPD
by: Chen R, et al.
Published: (2020-01-01)

Real-world effectiveness of umeclidinium/vilanterol versus fluticasone propionate/salmeterol as initial maintenance therapy for chronic obstructive pulmonary disease (COPD): a retrospective cohort study
by: Moretz C, et al.
Published: (2019-08-01)

LA inhalers for COPD: perceptions/reality of ABCD GOLD tool use
by: Varvara Boryushkina, et al.
Published: (2020-07-01)

Optimizing bronchodilation in the prevention of COPD exacerbations
by: Marc Miravitlles, et al.
Published: (2017-06-01)

Umeclidinium/Vilanterol Compared with Fluticasone Propionate/Salmeterol, Budesonide/Formoterol, and Tiotropium as Initial Maintenance Therapy in Patients with COPD Who Have High Costs and Comorbidities
by: Kalhan R, et al.
Published: (2021-04-01)

Efficacy of tiotropium–olodaterol fixed-dose combination in COPD
by: Derom E, et al.
Published: (2016-12-01)

Trends in prescriptions and costs of inhaled medications in chronic obstructive pulmonary disease: a 19-year population-based study from Canada
by: Tavakoli H, et al.
Published: (2019-09-01)

Inhaled therapies in patients with moderate COPD in clinical practice: current thinking
by: Ariel A, et al.
Published: (2017-12-01)

Elderly age group patients with COPD continuing to smoke -a problem that cannot be ignored
by: Vitalii I. Kupaev, et al.
Published: (2020-06-01)

The Effectiveness of 3 Combined Therapeutic Regimens in Egyptian Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease: A Randomized Double-Blind Prospective Pilot Study
by: Tarek M. Mostafa, et al.
Published: (2021-01-01)

Triple Therapy in COPD: Can We Welcome the Reduction in Cardiovascular Risk and Mortality?
by: Paolo Solidoro, et al.
Published: (2022-03-01)

Impact of COPD Exacerbations and Burden of Disease in Spain: AVOIDEX Study
by: Soler-Cataluña JJ, et al.
Published: (2023-06-01)

A Non-Interventional Study of Tiotropium/Olodaterol versus Any Triple Combination Therapy for Chronic Obstructive Pulmonary Disease: The EVELUT® Study Protocol
by: Buhl R, et al.
Published: (2020-10-01)

Time‐Dependent Risk of Cardiovascular Events Following an Exacerbation in Patients With Chronic Obstructive Pulmonary Disease: Post Hoc Analysis From the IMPACT Trial
by: Mark T. Dransfield, et al.
Published: (2022-09-01)

Day and Night Control of COPD and Role of Pharmacotherapy: A Review
by: Braghiroli A, et al.
Published: (2020-06-01)

An Evaluation Of Single And Dual Long-Acting Bronchodilator Therapy As Effective Interventions In Maintenance Therapy-Naïve Patients With COPD
by: Singh D, et al.
Published: (2019-12-01)

LABA/LAMA as First-Line Therapy for COPD: A Summary of the Evidence and Guideline Recommendations
by: Marc Miravitlles, et al.
Published: (2022-11-01)

Cost-effectiveness analysis of a fixed-dose combination of indacaterol and glycopyrronium as maintenance treatment for COPD
by: Chan M, et al.
Published: (2018-04-01)

Single Inhaler LABA/LAMA for COPD
by: Mario Malerba, et al.
Published: (2019-04-01)

Early COPD diagnosis and treatment: A case report
by: Roberto G. Carbone, et al.
Published: (2023-01-01)

Inhaler Devices for Delivery of LABA/LAMA Fixed-Dose Combinations in Patients with COPD
by: Anthony D’Urzo, et al.
Published: (2019-03-01)

Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials
by: Gary T. Ferguson, et al.
Published: (2020-05-01)

Effects of a single long-acting muscarinic antagonist agent and a long-acting muscarinic antagonist/long-acting β2-adrenoceptor agonist combination on lung function and symptoms in untreated COPD patients in Japan
by: Yamada H, et al.
Published: (2018-10-01)

Triple Therapy with Mometasone/Indacaterol/Glycopyrronium or Doubling the ICS/LABA Dose in GINA Step 4: IRIDIUM Analyses
by: Richard N. van Zyl-Smit, et al.
Published: (2023-08-01)

LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review
by: Rogliani P, et al.
Published: (2018-10-01)

GOLD in Practice: Chronic Obstructive Pulmonary Disease Treatment and Management in the Primary Care Setting
by: Yawn BP, et al.
Published: (2021-02-01)

A comparison of tiotropium, long-acting β2-agonists and leukotriene receptor antagonists on lung function and exacerbations in paediatric patients with asthma
by: Christian Vogelberg, et al.
Published: (2020-01-01)

Prognostic and functional impact of perioperative LAMA/LABA inhaled therapy in patients with lung cancer and chronic obstructive pulmonary disease
by: Yoko Azuma, et al.
Published: (2021-05-01)